PURPOSE: To our knowledge the association between dihydrotestosterone in the prostate and prostate cancer aggressiveness has not yet been elucidated. We analyzed dihydrotestosterone levels in the prostate and Gleason score in patients diagnosed with clinically localized prostate cancer. MATERIALS AND METHODS: A total of 81 patients with suspected prostate cancer underwent prostate biopsy. Serum samples were collected before biopsy. Dihydrotestosterone levels in prostatic tissue and serum were analyzed using liquid chromatography/electrospray ionization-mass spectrometry after polar derivatization. RESULTS: A total of 47 patients were diagnosed with stages T1 to T3N0M0 prostate cancer and 34 were diagnosed with no malignancy. Of the 47 patients 32 had a Gleason score of 6 or less and 15 had a score of 7 to 10. Dihydrotestosterone in prostatic tissue in patients with Gleason score 7 to 10 disease was significantly lower than in those with Gleason score 6 or less disease (p = 0.025). Gleason score correlated with the testosterone-to-serum dihydrotestosterone ratio (rs = 0.329, p = 0.038). CONCLUSIONS: Patients with Gleason score 7 to 10 prostate cancer have low dihydrotestosterone in the prostate, although there were no significant differences between patients with Gleason score 7 to 10 vs 6 or less prostate cancer with respect to serum androgens. Low dihydrotestosterone in cases of aggressive prostate cancer is probably sufficient to activate androgen receptor expression and propagate tumor growth.
PURPOSE: To our knowledge the association between dihydrotestosterone in the prostate and prostate cancer aggressiveness has not yet been elucidated. We analyzed dihydrotestosterone levels in the prostate and Gleason score in patients diagnosed with clinically localized prostate cancer. MATERIALS AND METHODS: A total of 81 patients with suspected prostate cancer underwent prostate biopsy. Serum samples were collected before biopsy. Dihydrotestosterone levels in prostatic tissue and serum were analyzed using liquid chromatography/electrospray ionization-mass spectrometry after polar derivatization. RESULTS: A total of 47 patients were diagnosed with stages T1 to T3N0M0 prostate cancer and 34 were diagnosed with no malignancy. Of the 47 patients 32 had a Gleason score of 6 or less and 15 had a score of 7 to 10. Dihydrotestosterone in prostatic tissue in patients with Gleason score 7 to 10 disease was significantly lower than in those with Gleason score 6 or less disease (p = 0.025). Gleason score correlated with the testosterone-to-serum dihydrotestosterone ratio (rs = 0.329, p = 0.038). CONCLUSIONS:Patients with Gleason score 7 to 10 prostate cancer have low dihydrotestosterone in the prostate, although there were no significant differences between patients with Gleason score 7 to 10 vs 6 or less prostate cancer with respect to serum androgens. Low dihydrotestosterone in cases of aggressive prostate cancer is probably sufficient to activate androgen receptor expression and propagate tumor growth.
Authors: Thomas Schnoeller; Florian Jentzmik; Ludwig Rinnab; Marcus V Cronauer; Ilija Damjanoski; Friedemann Zengerling; Andreas Al Ghazal; Mark Schrader; Andres J Schrader Journal: World J Urol Date: 2012-07-05 Impact factor: 4.226
Authors: Vivian N Hawkins; Karen Foster-Schubert; Jessica Chubak; Bess Sorensen; Cornelia M Ulrich; Frank Z Stancyzk; Stephen Plymate; Janet Stanford; Emily White; John D Potter; Anne McTiernan Journal: Med Sci Sports Exerc Date: 2008-02 Impact factor: 5.411
Authors: Bo Sung Shin; Eu Chang Hwang; Chang Min Im; Sun-Ouck Kim; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Kwangsung Park; Soo Bang Ryu Journal: Korean J Urol Date: 2010-12-21
Authors: Mazen Alsinnawi; Ailin Zhang; Daniella Bianchi-Frias; John Burns; Eunpi Cho; Xiaotun Zhang; Adam Sowalsky; Huihui Ye; April E Slee; Lawrence True; Christopher Porter; Mary-Ellen Taplin; Steven Balk; Peter S Nelson; R Bruce Montgomery; Elahe A Mostaghel Journal: Prostate Cancer Prostatic Dis Date: 2019-03-19 Impact factor: 5.554
Authors: Andrea Köhler; Ummühan Demir; Eva Kickstein; Sybille Krauss; Johanna Aigner; Beatriz Aranda-Orgillés; Antonios I Karagiannidis; Clemens Achmüller; Huajie Bu; Andrea Wunderlich; Michal-Ruth Schweiger; Georg Schaefer; Susann Schweiger; Helmut Klocker; Rainer Schneider Journal: Mol Cancer Date: 2014-06-09 Impact factor: 27.401